A detailed history of Grant transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Grant holds 13,156 shares of TARS stock, worth $631,488. This represents 0.4% of its overall portfolio holdings.

Number of Shares
13,156
Previous 39,299 66.52%
Holding current value
$631,488
Previous $2.18 Million 68.97%
% of portfolio
0.4%
Previous 1.22%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 01, 2025

SELL
$41.29 - $56.94 $1.08 Million - $1.49 Million
-26,143 Reduced 66.52%
13,156 $675,000
Q4 2024

Jan 15, 2025

SELL
$32.27 - $55.37 $462,461 - $793,507
-14,331 Reduced 26.72%
39,299 $2.18 Million
Q3 2024

Oct 15, 2024

BUY
$21.54 - $34.6 $646 - $1,038
30 Added 0.06%
53,630 $1.76 Million
Q2 2024

Jul 22, 2024

SELL
$25.17 - $38.73 $251 - $387
-10 Reduced 0.02%
53,600 $1.46 Million
Q3 2023

Oct 24, 2023

SELL
$14.75 - $24.62 $221 - $369
-15 Reduced 0.03%
53,610 $952,000
Q2 2023

Jul 19, 2023

BUY
$11.57 - $19.63 $620,441 - $1.05 Million
53,625 New
53,625 $969,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.28B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Grant Portfolio

Follow Grant and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Grant, based on Form 13F filings with the SEC.

News

Stay updated on Grant with notifications on news.